2023 World Conference on Lung Cancer (Posters)-P2.30. Assessing the Impact of Using Disease-Specific Novel Value Elements on Cost-Effectiveness Results in Lung Cancer

P2.30. Assessing the Impact of Using Disease-Specific Novel Value Elements on Cost-Effectiveness Results in Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the impact of using disease-specific novel value elements on cost-effectiveness results in lung cancer. Cost-effectiveness analyses compare new interventions with the current standard of care by incorporating clinical trial outcomes and healthcare costs. However, these analyses are limited by the use of nonspecific value elements from other disease areas. The study objectives were to identify previous cost-effectiveness studies that used nonspecific value elements in metastatic non-small cell lung cancer (mNSCLC) and to identify mNSCLC-specific value elements. <br /><br />The study used a targeted literature review in PubMed to identify relevant studies published between 2012 and 2022. The nonspecific value elements were informed by a previous cost-effectiveness analysis for second-line mNSCLC, while the mNSCLC-specific elements were identified through the literature review. These elements included patients' and caregivers' indirect costs, value of hope, option value, and insurance value. <br /><br />A cost-effectiveness model was developed to compare nivolumab plus ipilimumab (NI) as a first-line strategy for mNSCLC with platinum doublet chemotherapy (PDC) in the United Kingdom. The results showed that using nonspecific value elements underestimated the potential benefit of NI. When nonspecific elements were used, NI was associated with higher costs and higher quality-adjusted life-years (QALYs) compared to PDC. However, using mNSCLC-specific elements increased the incremental costs and QALYs. <br /><br />The net monetary benefit (NMB) associated with NI, calculated using mNSCLC-specific novel value elements, was higher than when nonspecific elements were used. This suggests that incorporating disease-specific novel value elements can provide a fuller understanding of the potential economic value of new therapies. The study concludes that further research should be conducted to identify and quantify disease-specific novel value elements for more accurate cost-effectiveness analyses.

Asset Subtitle

Yong Yuan

Meta Tag

Speaker Yong Yuan

Topic Global Health, Health Services & Health Economics: Health Economics

Keywords

impact assessment

disease-specific novel value elements

cost-effectiveness results

lung cancer

cost-effectiveness analyses

clinical trial outcomes

healthcare costs

metastatic non-small cell lung cancer

literature review

cost-effectiveness model